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ABSTRACT: 
Background/Purpose 
Fbxw7 is a tumor suppressor through ubiquitination and degradation of multiple 
oncoproteins. Loss of Fbxw7 is frequently observed in various human cancers. In this 
study, we examined the role of Fbxw7 expression in colorectal liver metastasis (CRLM) 
and its mechanism. 
Methods 
Fifty-six patients with CRLM who undergo curative resection were enrolled. 
Fbxw7 in tumor tissue was determined by immunohistochemistry. Patients were divided 
into two groups, the Fbxw7 high and low group. Clinicopathological factors including 
miR-223 expression were compared between the high (n=32) and low Fbxw7 group 
(n=24). 
Results 
Fbxw7 expression in tumor tissues was significantly lower than that in normal 
tissues. The disease-free survival in the low Fbxw7 group was significantly worse than 
that in the high Fbxw7 group, and 3years disease-free survival of the low and the high 
Fbxw7 group were 12.5% and 47.0%, respectively (p=0.023). On multivariate analysis, 
loss of Fbxw7 was detected as one of the independent risk factor for recurrence of 
CRLM (Hazard ratio: 2.390, p=0.017). Likewise, Fbxw7 expression inversely 
correlated to miR-223 expression (p=0.017). 
Conclusion 
Loss of Fbxw7 in tumor tissues could be a reliable predictor of recurrence after 
hepatectomy in patients with CRLM, and miR223 might be a possible regulator of 
Fbxw7. 
  
INTRODUCTION: 
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males 
and the second in females worldwide [1]. Liver is the most common site of metastasis 
from CRC [2]. Several clinicopathological features have been identified as prognostic 
factors in colorectal liver metastasis (CRLM) [3]. Recently, although nomogram has 
been reported for an index of the recurrence prediction after hepatic resection for 
CRLM from Japanese Society of Hepato-Biliary-Pancreatic Surgery (JHBPS) [4], the 
promising molecular target for malignant behavior has still been elucidated. 
F-box and WD repeat domain-contain 7 (Fbxw7) is a member of the F-box 
protein family. Fbxw7 serves as a substrate adaptor for the SKP1-CUL1-F-box protein 
(SCF) ubiquitin ligase complex. SCF ubiquitin ligase contributes to ubiquitin-dependent 
degradation of proteins with important role in the cell cycle, growth, and differentiation 
[5]. Fbxw7 acts as a tumor suppressor by targeting several oncogenic regulators such as 
cyclin E, c-Myc, Notch, Mcl-1, c-Jun, and mTOR [6]. Loss of Fbxw7 in tumor tissues 
correlates with a poor prognosis in several cancers [7, 8]. Recently, microRNAs (miRs) 
attracted attention as a mechanism for Fbxw7 regulation. miR-27a and miR-223 have 
been reported to be direct regulators of Fbxw7 in various types of carcinomas [9]. We 
also previously reported that the responder cases with rectal cancer for preoperative 
chemoradiotherapy indicated higher miR-223 compared with the non-responders [10]. 
Recently, increasing evidence suggests that miRNA-223 may also play an essential part 
in both hematological malignancies and solid tumors. As yet, the function of miR-223 in 
cancer has not been fully characterized and understood [11].  
To our knowledge, the correlation between Fbxw7 expression and prognostic 
effect for CRLM has never been reported. Also, its possible mechanism has been 
elucidated including its relationships to miR-223 in CRLM. Therefore, the aim of this 
study was to investigate the relationships between Fbxw7 expression and 
clinicopathological factors after curative hepatic resection (R0) and the role of miR-223 
as a Fbxw7 possible regulator for CRLM patients.  
  
METHODS: 
Patients 
Fifty-six patients with CRLM, who underwent curative hepatic resection (R0) in 
our institute from 2001 to 2009, were included in this study. The clinicopathological 
characteristics, including age, gender and pathology, were available for all patients. We 
excluded the patients who received non-curative surgical treatment (R1, R2) in not only 
primary tumor but CRLM, and had remote organ metastasis. Among all patients, there 
were 39 males and 17 females with a mean age of 63.9 years, ranging from 36 to 92 
years in age. Synchronous and metachronous CRLM were observed in 32 and 24 
patients, respectively. Regarding the primary region, 32 patients had colon cancer and 
24 patients had rectal cancer. The mean follow-up period of those 56 patients was 55.0 
months (range: 4.4–115.4 months).  
Regarding the classifications for extent of liver metastasis, H-stage classification 
and Grade classification were defined according to the Japanese Classification of 
Colorectal Carcinoma Second English Edition [12]. H-stage was based on number and 
largest size of liver metastasis. H1 was less than 4 number with diameter ≤ 5 cm. H2 
was more than 5 number or diameter > 5 cm. H3 was more than 5 metastases with 
diameter > 5 cm. Grade classification was based on H-stage, mesenteric lymph node 
metastases (pN0/1: ≤3 lesions, pN2: ≥4 lesions), and extrahepatic metastases (EM0: 
absence of extrahepatic metastasis, EM1: presence of extrahepatic metastases). Grade A 
was H1 and pN0/1, Grade B was H2 and pN0/1, or H1 and pN2. Grade C was H3 with 
any pN, or any H-stage and any pN with EM1.  
Of 24 cases with metacronous metastasis, there were 8 cases who underwent 
adjuvant chemotherapy after primary tumor resection and two of whom had CRLM 
during the period of adjuvant chemotherapy. Also, there were 37 cases who underwent 
adjuvant chemotherapy after hepatectomy for CRLM. The mean of time interval 
between primary tumor resection and liver metastasis in metachronous cases was 25.4 
months (range: 3.4-132.2 months). 
     This study was authorized in advance by the institutional review board of the 
University of Tokushima Graduate School (approved number; 2395).  
 
Quantitative real-time reverse transcription-PCR (qRT-PCR) 
The messenger RNA (mRNA) expression levels of Fbxw7 in tumor and 
non-tumor liver tissues from 44 patients were evaluated by qRT-PCR. The following 
assay (assay identification number) were used: Fbxw7 (Hs00217794_ml) and TaqMan 
human glyceraldehydes-3-phosphate dehydrogenase (GAPDH) endogeneous control 
(4326317E, Applied Biosystems) as the housekeeping gene. The mRNA expression 
levels were calculated as a ratio to that of GAPDH.  
The miR-223 expression levels in tumor and non-tumor liver tissues from 47 
patients were evaluated by qRT-PCR. The following assay were used: has-miR-223 
(2295) and RNU6B (001093, Applied Biosystems) as the housekeeping gene. The 
miR-223 expression levels were calculated as a ratio to that of U6 small nuclear RNA 
(RNU6B). 
 
Immunohistochemistry. 
Immunohistochemical staining was performind in surgical sections from 56 
patients according to previously described methods [7]. We used a rabbit polyclonal 
anti-Fbxw7 antibody (1:100, ab84873; Abcam, Cambridge, UK) as a primary antibody. 
Tissue sections were overlaid with 2nd antibody (Dako Real EnVision Kit/HRP, DAKO, 
Glostrup, Denmark). Peroxidase labeling was developed by incubating in 3,3´ 
deaminobenzidine tetrahydrochloride. Finally, nuclear counterstaining was completed 
using Meyer’s hematoxylin solution. Then, sections were dehydrated in alcohol and 
xylene and enclosed in synthetic resin. 
To evaluate Fbxw7 expression, the staining score was semiquantitatively 
calculated by the sum of the percentage score of cells stained at a given staining 
intensity (0, 0-25%; 1, 26-50%; 2, 51-75%; 3, 76-100%) and the staining intensity score 
(0, none; 1, weak; 2, moderate; 3, intense) (Fig. 1A-D). And those with a final score of 
more than 3 were considered high for Fbxw7 expression [7]. All immunohistochemical 
evaluation was performed by the pathologist who was given no information about 
individual CRLM. 
 
Statistical analysis. 
All statistical analyses were performed using JMP 11 statistical software (SAS 
Campus Drive, Cary, NC, USA). All results are expressed as the mean ± standard error. 
The Welch’s t test and Mann-Whitney U-test were used to compare continuous 
variables. The chi-squared test was applied for categorical data. Survival curves were 
calculated using the Kaplan-Meier method and compared using the log-rank test. All 
factors found to be significant by univariate analysis were included in the Cox’s 
proportional hazards model of multivariate analysis to identify independent factors 
influencing survival. A value of p<0.05 was considered statistically significant. 
  
RESULTS: 
The correlation between Fbxw7 expression and clinicopathological characteristics 
 Fbxw7 mRNA expression in tumor tissues was significantly lower than that of 
non-tumor tissues (p<0.001) (Fig. 2A). Moreover, Fbxw7 protein expression in tumor 
tissues was significantly lower than that of non-tumor tissues (p<0.0001) (Fig. 2B, C). 
The patients were divided into two groups: the high Fbxw7 (n=32) and the low (n=24) 
group in tumor tissues.  
Table 1 shows the comparison of clinicopathological characteristics according to 
Fbxw7 expression. There were no significant differences in the tumor factors, other than 
high carcinoembryonic antigen (CEA) level in the low Fbxw7 group (p=0.008). 
Regarding the regimen content and chemo-induction rate of adjuvant chemotherapy 
after hepatectomy, there was no significant difference between the two groups. 
There was no significant difference in overall survival (OS) between Fbxw7 high 
and low expression group. However, the disease-free survival (DFS) in the Fbxw7 low 
expression group was significantly worse than that in the high expression group, and 
3years disease-free survival rate were 12.5% and 47.0%, respectively (p=0.023) (Fig. 
3). 
 
Risk factors for tumor recurrence 
In the univariate analysis, metastatic grade B and C (p=0.032), synchronous liver 
metastasis (p<0.001), nomogram preoperative score ≥ 11 (p=0.039), and Fbxw7 low 
expression (p=0.023) were determined to be significant risk factors for tumor recurrence 
(Table 2). In the multivariable analysis, synchronous liver metastasis and Fbxw7 low 
expression were found to be the independent risk factors for tumor recurrence (Table 3). 
In respect to the recurrence pattern according to Fbxw7 expression in tumor tissues, 
there were no significant difference between Fbxw7 high and low expression group 
(Table 4). 
 
miR-223 expression and the relationship to Fbxw7 expression 
miR-223 expression in tumor tissues was significantly higher than that in 
non-tumor tissues (p=0.048) (Fig. 4A). Also, miR-223 expression in tumor tissues 
inversely correlated to the Fbxw7 expression (p=0.017) (Fig. 4B). We divided the 
patients into two groups: the high miR-223 group (n=37) and the low group (n=10) in 
tumor tissues according to miR-223 relative expression level (cut-off value: 1.3). The 
disease-free survival rate in the miR-223 high group was tended to be worse than that in 
the low group (p=0.124) (Fig. 4C). 
  
DISCUSSION: 
Fbxw7 is an important regulator of cell division and differentiation. Fbxw7 acts 
as tumor suppressor by ubiquitin-dependent degradation of several oncoproteins such as 
cyclin E, c-Myc, Notch, Mcl-1, c-Jun, and mTOR. The decline of Fbxw7 in tumor 
tissues has been observed to invite a poor prognosis in several types of the malignancy. 
In this study, we examined Fbxw7 expression in surgical specimen from patients with 
CRLM after curative hepatic resection. Consistent with previous reports, Fbxw7 
expression levels were significantly decreased in tumor tissues than that in normal liver 
tissues. In clinicopathological analyses, we found that patients with low Fbxw7 
expression in tumor tissues had significantly poorer disease-free survival. Furthermore, 
on the multivariate analysis, Fbxw7 was extracted as a more powerful independent 
recurrence defined factor compared to metastatic grade, synchronous metastasis and 
high preoperative score of nomogram. This suggests that loss of Fbxw7 in tumor tissues 
may be an important biomarker to predict postoperative recurrence in CRLM. 
Regarding the relationship between Fbxw7 and miRNAs, in the previous report, 
miR-27a was identified to inhibit the expression of FBW7. miR-27a was found to be 
overexpressed and inversely associated with FBW7 expression in leukemia [13]. Also, 
it was reported that miR-223 is associated with Fbxw7 expression. Kurashige et al. 
reported that inverse relationships between miR-223 and Fbxw7 in esophageal 
squamous cell carcinoma [9]. Li et al. also reported that Fbxw7 protein levels were 
inversely correlated with miR-223 expression in gastric tumor tissues [14]. Consistent 
with these findings, in the present study, we demonstrated that miR-223 expression was 
significantly higher in the low Fbxw7 group. Consequently, it considered the regulation 
of miR-223/Fbxw7 pathway, which miR-223 suppressed Fbxw7 expression. Moreover, 
patients with miR-223 high expression in tumor tissues tended that disease-free survival 
was worse. Regarding malignant behavior of miR-223, in the previous report, it was 
demonstrated that overexpression of miR-223 decreased Fbxw7 mRNA level, and 
enhanced c-Myc and c-Jun proteins expression in oesophageal squamous carcinoma cell 
lines [8]. Additionally, the mechanism was reported that miR-223 could negatively 
regulate the expression of Fbxw7 by directly targeting 3’ untranslated region (UTR) of 
Fbxw7 mRNA in gastric cancer cell lines, and overexpression of miR-223 induced 
tumor growth in vivo [14]. In another report, in T-cell acute lymphoblastic leukemia 
cell lines, it was observed the inverse correlation of miR-223 and Fbxw7 expression and 
that both Notch and NF-kB being able to activate cooperatively the transcriptional 
activity of miR-223 promoter [15]. Consistent with those studies, our findings suggested 
the involvement of miR-223/Fbxw7 pathway to poor prognosis in CRLM, and strongly 
suggested that miR-223/Fbxw7 pathway was an important target in CRLM. However, 
on the contrary, downregulation of miR-223 has been observed as worse prognostic 
factor in several types of malignancy, including osteosarcoma [16], hepatocellular 
carcinoma [17], esophageal carcinoma [18], and acute myeloid leukemia [19]. These 
previous reports demonstrated that miR-223 may have a side of the tumor suppressor. 
Taken together, while the regulatory mechanism of miR-223 has not been still 
elucidated, it could be a useful biomarker in various cancers. 
In addition, we have a discrepancy that there was no significant difference in 
overall survival, while disease-free survival was poor in Fbxw7 low expression groups. 
For one of the reasons, it may be the influence on the chemotherapy sensitivity via 
Fbxw7 expression. Previous studies have examined the relationship between Fbxw7 
expression and chemosensitivity. It was reported that the low Fbxw7 expression 
produced the resistance to chemotherapy such as taxol in non-small cell lung cancer 
[20] and doxorubicin in hepatocellular carcinoma [21] . On the other hands, another 
report revealed that Fbxw7 low expression group in cholangiocarcinoma patients 
certainly has poor prognosis, but interestingly they have high chemo-sensitivity [22]. 
Additionally, it was demonstrated that Fbxw7 depletion leads to the high sensitivity to 
imatinib in leukemia-initiating cells through c-Myc accumulation [23]. Thus, Fbxw7 is 
considered to have different role with respect to chemotherapy depending on cancer types 
and anti-cancer agents. In this study, although we were not able to prove the relationships 
between Fbxw7 and adjuvant chemotherapy, and it is the examination task for the future, 
but Fbxw7 may be expected as a clinical application to estimate the efficacy of 
chemosensitivity. 
Together, the present and previous findings supported the importance of 
conducting further investigations to determine the role of Fbxw7 in cancer for the 
biomarker for tumor recurrence and its mechanism. In conclusion, Fbxw7 low 
expression in tumor tissues was an independent risk factor for recurrence in CRLM after 
curative hepatic resection. miR223/Fbxw7 pathway might regulate the malignant 
behavior and be a molecular target for CRLM treatment. 
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Table 1. Comparison of clinicopathological features between Fbxw7 high and low 
expression in tumor tissues of colorectal liver metastasis. 
CEA, carcinoembryo antigen; CA19-9, carbohydrate antigen 19-9 
  
  Fbxw7 expression  
Factors  High (n=32) Low (n=24) p-value 
Metastatic tumor status     
  Age years 65.3 ± 4.3 62.0 ± 5.0 0.296 
  Gender Male / Female 24 / 8 15 / 9 0.315 
  CEA <100 / ≥100 30 / 2 16 / 8 0.008 
  CA19-9 <100 / ≥100 24 / 8 19 / 5 0.713 
  Tumor maximum diameter <5cm / ≥5cm 24 / 8 15 / 9 0.432 
  Tumor number <4 / ≥4 18 / 14 15 / 9 0.637 
  H Stage H1 / H2, H3 19 / 14 13 / 11 0.696 
  Grade A / B, C 14 / 16 9 / 14 0.582 
  Metastasis period synchronous / metachronous 17 / 15 15 / 9 0.482 
  Adjuvant chemotherapy yes / no 21 / 10 16 / 5 0.506 
    Fluoropyrimidine + / - 19 / 1 16 / 0 0.273 
    Oxaliplatin + / - 10 / 10 9 / 7 0.708 
    Irinotecan + / - 6 / 14 5 / 11 0.935 
    Bevacizumab + / - 1 / 19 3 / 13 0.188 
Primary tumor status     
  T 2, 3 / 4 24 / 5 21 / 2 0.361 
Location Colon / Rectum 19 / 13 13 / 11 0.696 
Grading (G1, 2, 3) 1 / 2, 3 7 / 22 5 / 16 0.978 
  Lymph node metastasis Positive / Negative 17 / 13 17 / 5 0.117 
Vascular invasion Positive / Negative 22 / 7 15 / 5 0.945 
  Adjuvant chemotherapy yes / no 4 / 8 4 / 3 0.310 
Table 2. Risk factor analysis for recurrence after hepatic resection of colorectal liver 
metastasis: univariate analysis.  
 
Factors  3-year survival 
(%) 
p-value 
Metastatic tumor status    
  Age <65 years / ≥65 years 25.0 / 41.2 0.429 
  Gender Male / Female 32.6 / 29.4 0.890 
  Tumor maximum diameter <5cm / ≥5cm 31.6 / 33.8 0.545 
  Tumor number <4 / ≥4 36.3 / 24.1 0.103 
  H Stage H1 / H2, H3 34.3 / 27.7 0.135 
  Grade A / B, C 36.3 / 20.9 0.032 
  Metastasis period Synchronous / metachronous 16.9 / 50.0 0.001 
  Adjuvant chemotherapy yes / no 27.8 / 43.6 0.535 
  Nomogram preoperative score <11 / ≥11 39.4 / 19.4 0.039 
  Fbxw7 expression High / Low 47.0 / 12.5 0.023 
Primary tumor status 
  T 2, 3 / 4 85.3 / 56.5 0.486 
Location Colon / Rectum 33.5 / 26.1 0.534 
  Differentiation Well / Other 45.4 / 25.6 0.126 
  Grading (G1, 2, 3) 1 / 2, 3 45.4 / 25.6 0.126 
Vascular invasion Positive / Negative 30.0 / 29.0 0.596 
  Adjuvant chemotherapy yes / no 50.0 / 54.5 0.820 
Table 3. Risk factor analysis for recurrence after hepatic resection for colorectal liver 
metastasis: multivariate analysis. 
CI, confidence interval. 
Factors Hazard Ratio 95% CI p-value
Grade B, C 1.437 0.674 – 3.123 0.348 
Metastasis period Synchronous 2.145 1.061 – 4.557 0.033 
Nomogram preoperative score ≥11 1.563 0.700 – 3.411 0.270 
Fbxw7 expression Low 2.390 1.169 – 4.964 0.017 
Table 4. Recurrent pattern after curative hepatectomy in colorectal liver metastasis 
according to Fbxw7 expression. 
Fbxw7 expression 
Recurrent site High (n=16) Low (n=21) p-value
Liver 12 (75.0%) 19 (90.4%) 0.206 
Lung 6 (37.5%) 7 (33.3%) 0.793 
Lymph node 4 (25.0%) 2 (9.5%) 0.206 
Bone 0 (0%) 1 (4.7%) 0.283 
Focal 0 (0%) 2 (9.5%) 0.125 
FIGURE LEGENDS: 
Figure 1. Immunohistochemical staining of Fbxw7 in colorectal liver metastasis 
(CRLM). 
(A) Fbxw7 none expression in tumor tissue of CRLM patients.
(B) Fbxw7 weak expression in tumor tissue of CRLM patients.
(C) Fbxw7 moderate expression in tumor tissue of CRLM patients.
(D) Fcxw7 intense expression in tumor tissue of CRLM patients.
Figure 2. Correlation of Fbxw7 expression with that in tumor and non-tumor tissues of 
colorectal liver metastasis (CRLM). 
(A) Fbxw7 mRNA relative expression by quantitative real-time reverse transcription
PCR.
(B) The representive picture of tumor infiltrating part in CRLM patients.
(C) Fbxw7 protein expression by immunohistochemical staining score. Fbxw7
expression levels in tumor tissues were significant lower than those in non-tumor tissues
of CRLM patients (p<0.0001).
Figure 3. Kaplan–Meier analysis of (A) overall survival and (B) disease-free survival in 
colorectal liver metastasis patients with high and low Fbxw7 expression. 
Figure 4 miR-223 expression in colorectal liver metastasis (CRLM). 
(A) Comparison of miR-223 expression in the tumor and non-tumor tissues of CRLM
patients. miR-223 expression in tumor tissues was significantly higher than those in
non-tumor tissues.
(B) Correlation between Fbxw7 expression and miR-223 expresion in the tumor tissues
of CRLM patients. miR-223 expression in Fbxw7 low expression group was
significantly higher than those in Fbxw7 high expression group.
(C) Disease-free survival rate according to miR-223 expression in tumor tissues of
CRLM patients. DFS in miR-223 high expression group was tended to be worse than
those in miR-223 low expression group.
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